Patent · US Active

Protease-sensitive site in apolipoprotein A1, therapeutic and diagnostic implications

US8343932B2 · kind B2 · utility

2Cited by

1References

9Claims

0Family size

Assignee

Pronota N.V. · BE

Inventors

Sven Eyckerman · Nazareth, BE
Koen Kas · Schilde, BE
Christine Labeur · Brugge, BE

Key dates

Filing date	Oct 17, 2008
Grant date	Jan 1, 2013
Priority date	—
Expiry date	Jun 17, 2029

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K38/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to the identification of a naturally occurring internal proteolytic cleavage site in the ApoA1 protein, which leads to inactivation of the mature protein. Specific modification of this cleavage site leads to a stabilised ApoA1 protein, which is beneficial for the reverse cholesterol transport. The invention therefore encompasses pharmaceutical compositions comprising a recombinant stabilised variant ApoA1 protein or rHDL particles comprising such a protein, for use in the treatment of patients having reduced HDL or hampered reverse cholesterol transport.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.